William Walsh, MD
Addiction Medicine · Ogden, UTNPI 1730374604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,635 of the $3,276 with a category attached, or 80.4%. It is spread thinly across 25 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,583, more than ten times the $29 reported in 2019. Among addiction medicine clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BD$543
- Indivior Inc.$455
- Novo Nordisk$273
- GSK$232
- Corcept Therapeutics$207
- Edwards Lifesciences$202
- plus $1K from 19 others
Across 39 payments — averaging $18,072 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$492K
- Abbott$131K
- AstraZeneca$70K
- Cleerly, Inc.$12K
What the payments were for
- Consulting fees$54317%
- Food & beverage$2,63580%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BD | 2 | $543 |
| Indivior Inc. | 21 | $455 |
| Novo Nordisk | 5 | $273 |
| GSK | 3 | $232 |
| Corcept Therapeutics | 5 | $207 |
| Edwards Lifesciences | 1 | $202 |
| AstraZeneca | 4 | $167 |
| Astellas Pharma US Inc | 4 | $161 |
| Lilly USA, LLC | 4 | $133 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| AbbVie | 6 | $121 |
| Boston Scientific | 2 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $108 |
| Inspire Medical Systems, Inc. | 2 | $84 |
| Alkermes, Inc. | 1 | $73 |
| Merck | 1 | $67 |
| Pfizer | 3 | $43 |
| Davol Inc. | 1 | $39 |
| Braeburn Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| Seqirus USA Inc | 1 | $19 |
| Cranial Technologies, Inc | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$202
- Korlym$138
- AREXVY$125
- VOQUEZNA$125
- Ozempic$122
How this compares
$3,276 in reported general payments places this provider in the 90th percentile of 21 addiction medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $43,758 |
| JardianceEmpagliflozin | 32 | $29,402 |
| FarxigaDapagliflozin Propanediol | 25 | $18,226 |
| OzempicSemaglutide | 12 | $16,808 |
| MounjaroTirzepatide | 15 | $16,128 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,449 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,466 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $4,038 |
| Buprenorphine Hcl | 48 | $2,002 |
| Gabapentin | 101 | $1,362 |
| Estradiol (Once Weekly)Estradiol | 11 | $938 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $909 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $903 |
| Pregabalin | 38 | $854 |
| Estradiol | 15 | $842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $43,75856 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $167 | $29,67539 claims |
| Novo NordiskOzempic | $273 | $16,80812 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $133 | $16,45835 claims |
| GSKTrelegy Ellipta | $232 | $8,46613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 addiction medicine providers in Utah.
Other addiction medicine in Ogden
- Amy de la GarzaSalt Lake City$8K
- Megan SchwartzMagna$5K
- Robert BushProvo$2K
- Barry KingOrem$1K
- Cuicui ZhangSandy$1K
- Terrell SellersMidway$563
- David AuneSalt Lake City$315
- Ronald BairdWest Jordan$296
- Charles CanfieldSouth Jordan$257
- Anna TsygelnytskaSalt Lake City$218
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.